Patents by Inventor Yong-Woon Jung

Yong-Woon Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10259781
    Abstract: Provided herein is technology relating to imaging agents and particularly, but not exclusively, to methods of manufacturing fluorine-18-labeled phenethylguanidines and uses thereof.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 16, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David M. Raffel, Yong-Woon Jung, Keun-Sam Jang
  • Publication number: 20180230088
    Abstract: Provided herein is technology relating to imaging agents and particularly, but not exclusively, to methods of manufacturing fluorine-18-labeled phenethylguanidines and uses thereof.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 16, 2018
    Inventors: David M. Raffel, Yong-Woon Jung, Keun-Sam Jang
  • Publication number: 20170190658
    Abstract: Provided herein is technology relating to imaging agents and particularly, but not exclusively, to methods of manufacturing fluorine-18-labeled phenethylguanidines and uses thereof.
    Type: Application
    Filed: December 2, 2016
    Publication date: July 6, 2017
    Inventors: David M. Raffel, Yong-Woon Jung, Keun-Sam Jang
  • Publication number: 20150246142
    Abstract: Provided herein is technology relating to imaging agents and particularly, but not exclusively, to methods of manufacturing fluorine-18-labeled phenethylguanidines and uses thereof.
    Type: Application
    Filed: September 25, 2013
    Publication date: September 3, 2015
    Inventors: David M. Raffel, Yong-Woon Jung, Keun-Sam Jang
  • Patent number: 7534418
    Abstract: The present invention provides novel compounds that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging). The present invention also provides imaging compositions for use within nuclear medicine applications. Additionally, the present invention provides methods of imaging.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: May 19, 2009
    Assignee: The Regents of the University of Michigan
    Inventors: David M. Raffel, Yong-Woon Jung, David L. Gildersleeve
  • Publication number: 20060127309
    Abstract: The present invention provides novel compounds that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging). The present invention also provides imaging compositions for use within nuclear medicine applications. Additionally, the present invention provides methods of imaging.
    Type: Application
    Filed: December 10, 2004
    Publication date: June 15, 2006
    Applicant: The Regents of the University of Michigan
    Inventors: David Raffel, Yong-Woon Jung, David Gildersleeve
  • Patent number: 5077035
    Abstract: Radioiodinated benzovesamicol analogs which selectively localize in presynaptic cholinergic neurons of the general formula: ##STR1## where X is selected from the group consisting of H, OH, NH.sub.2, NHCO-3-[I]-Ph, and a radioactive isotope of iodine, and Y is selected from the group of H and a radioactive isotope of iodine, Y being H is X contains iodine. Illustrative examples include: (.+-.)-trans-2-hydroxy-5-iodo-3-(4-phenylpiperidino)tetralin; (.+-.)-trans-3-hydroxy-5-iodo-2-(4-phenylpiperidino)tetralin; (.+-.)-trans-5-amino-2-hydroxy-8-iodo-3-(4-phenylpiperidino)tetralin; and (.+-.)-trans-2-hydroxy-5-(3-iodobenzamido)-3-(4-phenylpiperidino)tetralin. The novel radioiodinated benzovesamicol analogs may be used as radiopharmaceuticals to visualize cholinergic neurons with conventional imaging devices which are typically found in most nuclear medicine or radiology clinics.
    Type: Grant
    Filed: May 14, 1990
    Date of Patent: December 31, 1991
    Assignee: The University of Michigan
    Inventors: Donald M. Wieland, Yong-Woon Jung, Marcian E. Van Dort, David L. Gildersleeve